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Background: Therapeutic cancer vaccines aim to boost the natural immunity against transformed cancer cells, and
a series of adjuvants and co-stimulatory molecules have been proposed to enhance the immune response against
weak self-antigens expressed on cancer cells. For instance, a peptide/CpG-based cancer vaccine has been evaluated
in several clinical trials and was shown in pre-clinical studies to favor the expansion of effector T versus Tregs cells,
resulting in a potent antitumor activity, as compared to other TLR ligands. Alternatively, the adjuvant activity of
CD1d-restricted invariant NKT cells (iNKT) on the innate and adaptive immunity is well demonstrated, and several
CD1d glycolipid ligands are under pre-clinical and clinical evaluation. Importantly, additive or even synergistic effects
have been shown upon combined CD1d/NKT agonists and TLR ligands. The aim of the present study is to combine
the activation and tumor targeting of activated iNKT, NK and T cells.
Methods: Activation and tumor targeting of iNKT cells via recombinant α-galactosylceramide (αGC)-loaded
CD1d-anti-HER2 fusion protein (CD1d-antitumor) is combined or not with OVA peptide/CpG vaccine. Circulating
and intratumoral NK and H-2Kb/OVA-specific CD8 responses are monitored, as well as the state of activation of
dendritic cells (DC) with regard to activation markers and IL-12 secretion. The resulting antitumor therapy is
tested against established tumor grafts of B16 melanoma cells expressing human HER2 and ovalbumin.
Results: The combined CD1d/iNKT antitumor therapy and CpG/peptide-based immunization leads to optimized
expansion of NK and OVA-specific CD8 T cells (CTLs), likely resulting from the maturation of highly pro-inflammatory
DCs as seen by a synergistic increase in serum IL-12. The enhanced innate and adaptive immune responses
result in higher tumor inhibition that correlates with increased numbers of OVA-specific CTLs at the tumor site.
Antibody-mediated depletion experiments further demonstrate that in this context, CTLs rather than NK cells are
essential for the enhanced tumor inhibition.
Conclusions: Altogether, our study in mice demonstrates that αGC/CD1d-antitumor fusion protein greatly
increases the efficacy of a therapeutic CpG-based cancer vaccine, first as an adjuvant during T cell priming and
second, as a therapeutic agent to redirect immune responses to the tumor site.
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The importance of immune surveillance in eradicating ma-
lignant cells is well demonstrated, and several observations
have motivated the development of therapeutic cancer
vaccines. However, except for virus-induced cancers, tumor
antigens are mostly self or near-self protein epitopes that
are often poorly immunogenic and submitted to central
and peripheral tolerance. For therapeutic cancer vaccines to
be effective, they must overcome regulatory and immuno-
suppressive mechanisms raised by the immune system itself
and by the tumor microenvironment [1,2]. It is now well
demonstrated that DCs are the central cell population
making the decision between immunity or immune toler-
ance, depending on the stimuli that they receive [2,3]. For
instance, the development of tolerogenic DCs will lead to
antigen tolerance in particular through the expansion of T
regulatory cells (Tregs). We have recently shown that the
vaccine formulation, and in particular the presence of the
Toll-like Receptor (TLR) agonist CpG, can significantly
promote the maturation of pro-inflammatory DCs, which
favors Type I T cell responses while restricting the expansion
of Tregs [4]. In addition to TLR ligands, CD1d-restricted
invariant NKT (iNKT) cells have been shown to efficiently
promote the transactivation of DCs through the CD40L-
CD40 interaction upon recognition of the CD1d-glycolipid
antigen complex by their semi-invariant TCR. In view of
the capacity of iNKT cells to promote DC maturation and
NK cell transactivation, several pre-clinical studies have
investigated the use of the CD1d/iNKT super agonist α-
galactosylceramide (αGalCer), or a related analog as vaccine
adjuvant [5-7]. More recently, several studies have demon-
strated a cooperative effect on DC maturation between
TLR ligands and iNKT cell activation, resulting in highly
pro-inflammatory DCs, as seen by enhanced expression of
activation markers [8-10]. However, if generating pro-
inflammatory DCs should result in a good expansion of
antigen-specific T cells, it will not guarantee their efficient
homing to the tumor, unless a targeting strategy is used. In
this context, we have developed CD1d-antitumor fusion
proteins consisting of the soluble part of the CD1d molecule
fused to a scFv antibody fragment specific for the tumor an-
tigens CEA or HER2. We have previously demonstrated
in vitro and in vivo that these fusion proteins were able to
redirect iNKT, NK and T cells to the tumor expressing the
relevant antigen resulting in a potent antitumor effect
[11,12]. In the present study, we aimed to combine a CpG-
based peptide vaccine with the activation and tumor target-
ing of iNKTcells via the CD1d-anti-HER2 fusion protein.
Results
αGC/CD1d-mediated activation of iNKT cells combined
with CpG-ODN promote highly pro-inflammatory DCs
We, and others, have previously reported that iNKT
cells and TLR ligands are both potent inducers ofpro-inflammatory DCs [2,4,7]. In the present study,
we evaluated the possible synergy on the maturation
of DCs when combining the αGC/CD1d-antitumor fusion
protein treatment with CpG-based peptide vaccine. In this
regard, mice transferred with Vα14-Jα18 and OT-I
splenocytes and immunized with OVA peptide alone
or in combination with CpG or CD1d-fus/CpG were
sacrificed 20 hours after i.m. immunization. Indeed, expres-
sion of CD40, CD86, and MHC-II on CD8α+ CD11c+ DCs,
as identified by using the gating strategy depicted in
Additional file 1: Figure S1, was enhanced upon treatment
with the combined stimuli, as compared to the CD1d-scFv
fusion or CpG as single agent (Figure 1B and C and data
not shown). Moreover, the expression of CD70 essential
for the priming of naïve CD8 T cells [13,14] was not
affected by each stimulus alone, but was significantly
up-regulated upon the combined CD1d-fusion and CpG
treatment (Figure 1D). Interestingly, the up-regulation of
CD86 and CD40 was much weaker in the CD8αneg DC
and B220+CD11c+ pDC subsets, and was similar upon
individual or combined treatments (Figure 1A). These
observations strongly suggest that CD8α+ DCs were the
main DC population simultaneously triggered through
TLR-9 by CpG ODN and by activated iNKT cells via
CD40-CD40L. Finally, the major observation was the
synergistic production of IL-12p70 in the serum six hours
after the combined treatment (Figure 1E). Indeed, the
circulating level of this cytokine was ten times higher
in mice treated with the combination of CD1d-fusion
and OVA/CpG-ODN than with the CD1d-fusion or
OVA/CpG-ODN alone (Figure 1E). Altogether, these
results demonstrate the potential of combined activation
of iNKT cells and direct stimulation with a TLR-9 ligand
in promoting highly pro-inflammatory cross-presenting
CD8α+ DCs.
Optimal priming of OVA-specific CTLs and expansion of
NK cells upon combined CD1d treatment and OVA/CpG
immunization
Next, we evaluated whether the optimal maturation of
CD8α+ DCs would result in increased T cell priming after
intramuscular administration of the CD1d-immunotherapy
together with OVA/CpG-ODN vaccine in mice transferred
with Vα14-Jα18 and OT-I cells. Indeed, already at day 3
post-immunization, increased frequencies of OVA-specific
CD8 T cells were observed in the blood of mice treated
with the combined treatment, as compared to the OVA/
CpG-ODN immunization alone (Figure 2A, left). The
superior CD8 T cell priming with the combined settings
reached statistical significance at day 7 in the spleen,
when compared to all the other groups, including OVA/
CpG-ODN immunization alone (Figure 2B, left). Acti-
vated iNKT cells are well known to transactivate NK
cells [15,16], as further confirmed in the present study
Figure 1 Optimal maturation of CD8α+ DCs after CD1d-mediated activation of iNKT cells combined with CpG-ODN. Mice transferred with
Vα14-Jα18 and OT-I splenocytes were immunized i.m. with OVA peptide alone or in combination with CpG or CD1d-fus/CpG followed or not by
systemic treatment with the CD1d-antitumor protein. Mice were bled after 6 hours and sacrificed 20 hours after i.m. immunization. A. Twenty
hours post immunization, splenic DC subsets were discriminated according to the gating strategy described in Additional file 1: Figure S1, and
each subset was analyzed for the expression of CD40 and CD86 maturation markers. Data are shown as histogram overlays of the different
treatment groups as indicated. B. Mean fluorescence intensity of CD40 on gated CD8α+DCs. C. Mean fluorescence intensity of CD86 on gated
CD8α+DCs. D. Mean fluorescence intensity of CD70 on gated CD8α+DCs. E. Sera from mice were collected 6 hours after the immunization and
IL-12p70 was measured using a BD flex set assay. Bar graphs show mean of fluorescence or cytokine level in pg/ml as mean +/− SEM for 3 samples
per group. Data are representative of 2 independent experiments. *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.
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Figure 2 Expansion of OVA-specific CTLs and NK cells upon combined CD1d treatment and OVA/CpG immunization. Blood and spleen
lymphocytes from CD45.1 mice that received Vα14-Jα18 and OT-I cells and were immunized and treated as in Fig. 1, were monitored at different time
points after immunization. A. Left; frequency of H-2Kb/OVA-specific CD8 T cells among total CD8 lymphocytes in the blood at day 3 after immunization.
Right; frequency of NK cells in the blood at the same time point. B. Left; frequency of H-2Kb/OVA-specific CD8 T cells among total CD8 lymphocytes in
the spleen at day 7 after the immunization. Right; frequency of NK cells among total lymphocytes at the same time point. C. Left; total numbers of
H-2Kb/OVA-specific CD8 T cells in the spleen at day 7. Right; total numbers of NK cells in the spleen at the same time point. Bar graphs show frequencies
as mean +/− SEM of groups of 5 or 3 mice. Data are representative of 3 independent experiments. *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.
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Interestingly, the combined CD1d immunotherapy and
peptide/CpG-ODN immunization resulted in a synergistic
effect on the expansion of NK cells with a threefold in-
creased frequency at day 7 in the spleen (Figure 2B, right),
while peptide/CpG-ODN vaccine alone had no effect on
NK cells. The increase in CD8 and NK cell frequenciesin response to the combined stimuli was mirrored by an
increase in total cell numbers (Figure 2C). Finally, an
additive effect of combined stimuli on NK cell activa-
tion was already seen in the spleen twenty hours after
immunization by CD69 up-regulation (Additional file 2:
Figure S2A). Whereas iNKT cell-mediated transactivation
of DCs, CTLs and NK cells was clearly seen by up-
Figure 3 Serum levels of cytokine upon combined CD1d
treatment and OVA/CpG immunization. Mice were immunised
i.m. with OVA peptide alone or in combination with CpG or
CD1d-fus/CpG following Vα14-Jα18 and OT-I cell transfer and treated
or not systemically with CD1d-fus. Sera were collected 20 hours after
the different immunisations and cytokine levels were measured
using the Th1/Th2/Th17 CBA assay. A. Serum IFNγ level. B. Serum
TNFα level. C. Serum IL-6 level. Bar graphs show cytokine level in pg/ml
as mean +/− SEM for 3 samples per group. Data are representative of 3
independent experiments. *, p <0.05; ***, p <0.001.
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in vivo activation of iNKT cells themselves was rather
revealed by their quick disappearance due to their TCR
down-regulation (data not shown). However, their fast
activation by the CD1d-anti-HER2 fusion protein could be
detected in vitro by their mild increased frequency and
by a significant up-regulation of CD69 (Additional file 2:
Figure S2B).
In light of the robust response induced by combination
therapy in the OVA model, we sought to test whether it
would also work successfully as a stand-alone therapy to
generate endogenous immune responses against a natural
tumor/self antigen. To test this hypothesis, we vaccinated
mice with the peptide Trp2180–188 from the melanoma
antigen tyrosinase-related protein 2, either alone, with
CpG-ODN, or in combination with both CpG-ODN and
CD1d-HER2 fusion protein. In Additional file 3: Figure
S3A, we show that the combination treatment signifi-
cantly increased the frequency of endogenous H-2Kb/
Trp2-specific CD8+ T cells over that of the peptide
vaccine alone. There was also a slight increase over the
peptide + CpG-ODN vaccine. Additionally, NK cell fre-
quencies were increased, over both the peptide and
peptide + CpG-ODN vaccines in response to the combin-
ation treatment, to the same extent as in the OT-I model
(Additional file 3: Figure S3B). Altogether, the CD1d-
mediated activation of iNKT cells combined with the
TLR9 ligand resulted in an overall synergistic effect on the
innate and adaptive immune responses.
Enhanced serum levels of TH1 cytokines upon combined
CD1d treatment and OVA/CpG immunization
The optimal maturation of pro-inflammatory DCs leading
to the expansion and activation of OVA-specific CD8 T
cells and NK cells, were correlated with detectable serum
levels of TH1 cytokines. Indeed, twenty hours after the
combined CD1d-fusion and OVA/CpG-ODN i.m. injec-
tion in mice transferred with Vα14-Jα18 and OT-I cells,
IFNγ, TNFα and IL-6 were significantly increased, as
compared to each single stimulus (Figure 3). In contrast,
the OVA/CpG-ODN alone was able to promote the pro-
duction of IL-6 and TNFα, indicators of the maturation of
pro-inflammatory DCs, but only a small quantity of IFNγ
was detected. As expected, the CD1d immunotherapy
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to TNFα and IL-6, resulting from the concomitant
activation of iNKT and NK cells. Noteworthy, at the same
time point, the cytokines IL-4 and IL-10 belonging to the
TH2/regulatory T cell profile, as well as IL-17a, were
undetectable in the sera of all the mice, whatever the
treatment. Altogether, the levels of TH1 cytokines detected
shortly after the immunization confirmed the efficacy of
the combined CD1d-fusion and CpG-based vaccine in
activating the innate immune response.Figure 4 Combined OVA/CpG vaccine and CD1d-antitumor fusion lea
OVA-specific CTLs at the tumor site. Recipient CD45.1 mice were grafted
transfer and 5 days later, they were immunized and treated as described in
mean tumor volume (mm3) +/− SEM of 5 mice/group. B-C. Mice were sacrific
CD8 T cells among total tumor infiltrating CD8 T lymphocytes and C, frequen
graphs show frequencies as mean +/− SEM of groups of 3 mice. Data are rep
***, p <0.001; ****, p <0.0001.Enhanced antitumor efficacy of combined CD1d/CpG
immunotherapy correlates with accumulation of
OVA-specific CTLs at the tumor site
We next assessed the antitumor capacity of the combined
CD1d/CpG immunotherapy (Figure 4A). Mice were grafted
s.c. with B16-OVA-HER2 tumor cells, that co-express
ovalbumin intracellularly and human HER2 on the cell
surface following Vα14-Jα18 and OT-I transfer. On day 6,
when all tumors were palpable, mice were immunized with
the single or combined regimens i.m., and then treated ord to enhanced antitumor effects correlating with accumulation of
s.c. with B16-OVA-HER2 tumor cells following Vα14-Jα18 and OT-I
Figure 1 and in the Methods. A. Kinetic of tumor growth shown as
ed 7 days after the immunisation and B, frequency of H-2Kb/OVA-specific
cy of NK cells among total tumor lymphocytes were measured. Bar
resentative of 3 independent experiments. *, p <0.05; **, p <0.01;
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three or four days in view of the transient downmodulation
of the iNKT TCR [12,17]. As expected from the optimal T
cell response, tumor growth was best delayed in mice
treated with the combination of CD1d-fusion therapy and
OVA/CpG-ODN vaccine (Figure 4A), as compared to the
CD1d-fusion therapy or the OVA/CpG-ODN vaccine as
single agents. As a negative control, mice immunized with
the OVA peptide alone showed fast tumor growth. The
importance of OVA-specific CTLs among tumor infiltrat-
ing lymphocytes was suggested by a two-fold increase of
OVA-specific CD8 T cells when the OVA/CpG-ODN
vaccine was combined with the CD1d-therapy compared to
the vaccine alone (Figure 4B). Regarding NK cells, the
CD1d-fusion therapy induced a significantly increased infil-
tration of NK cells that was similar whether associated or
not with the OVA/CpG-ODN vaccine, suggesting that the
superior antitumor activity seen upon the combined treat-
ment, resulted primarily from enhanced CTL-mediated
cytotoxicity at this timepoint (Figure 4C).Figure 5 Antibody-mediated depletion demonstrates that CD8
T cells rather than NK cells are essential for the combined
antitumor effect. Recipient CD45.1 mice were grafted s.c. with 500
000 B16-OVA-HER2 tumor cells following Vα14-Jα18 and OT-I transfer
and were immunized and treated 5 days later as described in Fig-
ure 1. For depletion of CD8 T cells or NK cells, repeated injections
of respectively anti-CD8 or anti-asialo-GM1 antibodies were ad-
ministered as described in the Methods. A. Kinetic of tumor
growth shown as mean tumor volume (mm3) +/− SEM of 7 mice/
group. B. Same results zooming in on non-depleted and NK de-
pleted groups. *, p <0.05; **, p <0.01; ***, p <0.001.Antibody-mediated depletion demonstrates that CD8 T
cells rather than NK cells are essential for the combined
antitumor effect
To assess the respective role of OVA-specific CTLs and
NK cells in the delayed tumor growth, antibody-mediated
cell depletion was performed with anti-CD8α or anti-
asialo-GM1 antibodies, respectively. Groups of seven mice
received Vα14-Jα18 and OT-I cells and one or the other
antibody was then administered two days before tumor
graft and once every three days thereafter, for a total of
four injections. CD1d-antitumor therapy combined with
OVA/CpG-ODN vaccination was essentially done as
above. Strikingly, the inhibition of tumor growth was
completely abolished upon depletion of CD8 T cells, while
NK cell depletion had little consequence on the prolonged
antitumor effect (Figure 5A). When CD8 T cells were
absent a complete loss of antitumor effect was achieved
and the tumor growth became similar to that obtained
with non-treated mice (Figure 5A). Regarding the role of
NK cells, the tumor growth in NK-depleted mice re-
sembled to that of non-depleted mice in the long-term.
However, a discrete but visible loss of antitumor activity
was observed from day 11 to day 16, implicating a role for
NK cells in early tumor regression (Figure 5B). The weak
impact of NK cells in the antitumor effects correlated with
their low enrichment in the tumor tissues and in parallel,
the strong impact of CD8 T cells was associated with a
large accumulation of antigen-specific CD8 T cells in tu-
mors. Overall, these data demonstrate the important role
of CTLs in the antitumor effects observed for this melan-
oma model after the combined CD1d-immunotherapy
and OVA/CpG-ODN vaccine.Discussion
In most cases, immature DCs will induce tolerance when
encountering a tumor-derived self-antigen, unless danger
signals are provided. Therefore, one key element for a
successful vaccine formulation is to favor the maturation of
pro-inflammatory DCs in order to induce a potent
adaptive immune response against cancer cells. To this
aim, TLR ligands represent potent danger signals able to
induce the maturation of TH1-biased DCs, and are often
involved in cancer vaccine formulations [18]. We recently
demonstrated that peptide antigens combined in particu-
lar with Poly(I:C) (TLR-3) or CpG ODN (TLR-9) were
optimal formulations leading to higher IL-12 serum levels
and increased Teff to Treg ratio, which in turn resulted in
increased antitumor effects, as compared to other TLR
ligands [4]. However, despite the success of cancer
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egies have had only limited success in humans. In 2004,
Rosenberg et al. analysed the outcome of 86 therapeutic
vaccination trials in a range of different cancers, and
discovered an overall objective clinical response rate of
only 3.3% [19]. A more recent review showed some
promising advances with therapeutic vaccines but complete
clinical responses are still rare [20]. The most successful
vaccination strategies appear to be those where vaccines are
combined with chemotherapy, immune check-point block-
ade or novel adjuvant formulations, indicating that combin-
ation therapies are the way of future vaccine design.
In the present study, the antitumor therapeutic effects
of peptide/CpG ODN vaccine were further enhanced by
combining with the specific activation of iNKT cells via
αGC/sCD1d-antitumor fusion proteins, which we previ-
ously developed to redirect the innate and adaptive im-
mune responses to the tumor site [11,12]. Most strikingly,
the combined treatment resulted in a synergistic increase
in serum IL-12, denoting an optimal maturation of pro-
inflammatory DCs. The second major observation was
that CD8α+ DC appeared to be the major responders to
the combined immunization with peptide/CpG/CD1d-fu-
sion, as seen especially by their much superior increase in
CD40 and to a lesser extent in CD86 expression, when
compared to CD8αneg and pDC subsets. Recent studies
have already demonstrated the tight collaboration between
iNKT cells and cross-presenting CD8α+ DCs, and their
importance in generating long-term CD8 T cell memory
[21,22]. The immunoregulatory role of CD1d-restricted
iNKT cells in the transactivation of innate and adaptive
immune responses has been well demonstrated [7,23], and
several studies have exploited iNKT cells for therapeutic
cancer vaccination [24,25]. One major advantage is that
iNKT cells represent a readily available source of help for
DCs, as they do not require antigen priming like naïve
CD4 T cells do [26]. The crosstalk between iNKT cells and
DCs depends on both the invariant TCR-CD1d/glycolipid
antigen and CD40L-CD40 interaction, which will guaran-
tee a subsequent efficient T cell priming [27]. Indeed, we
show in the present study that upon combined peptide/
CpG-ODN vaccine and αGC/CD1d-antitumor fusion
protein, DC maturation markers including CD40, CD86
and CD70 were significantly increased as compared to
individual treatment. In addition to DC maturation, the
combined peptide/CpG-ODN vaccine and αGC/sCD1d-
antitumor fusion protein also resulted in a synergistic
expansion of NK cells as seen in the spleen on day 7.
iNKT cells are well-known to quickly transactivate NK
cells directly via their release of IFNγ and indirectly via
their crosstalk with DCs [28,29]. In this context, the
strong IL-12 release by DCs upon the combined treatment
in addition to IFNγ, likely explains the large expansion of
NK cells. Importantly, in view of their respective adjuvanteffect on the adaptive immune response, we also observed
a cooperative effect of peptide/CpG-ODN and αGC/
CD1d-antitumor treatment on the expansion of H-2Kb/
OVA specific CD8 T cells. Altogether, the enhanced
innate and adaptive responses to the combined treatment
correlated well with significantly higher serum levels of
TH1 cytokines such as IFNγ, TNFα and IL-6. This coopera-
tive effect was also observed when triggering the expansion
of endogenous H-2Kb/Trp2 specific CD8 T cells, as de-
scribed in Additional file 3: Figure S3. However, while
the large expansion of NK cells was just as robust as
that observed in the OT-I/Vα14-Jα18 transfer model,
the frequencies of Trp-2-specific T cells remained about
fivefold less than for OT-I T cells. This weaker frequency
possibly reflects the more stringent conditions required to
induce the expansion of tumor/self antigen-specific T
cells, which are likely to be present at a low frequency and
to have a high activation threshold compared to transgenic
CD8+ T cells. This highlights the advantage of combining
a CD8 T cell vaccine with CD1d-fusion protein, which
harnesses the innate immune response to boost the adap-
tive response and enhance anti-tumor immunity. These
combined adjuvant effects between TLR ligands and the
CD1d superagonist αGC have been reported previously
for TLR-3, 4 and 9 [9,30]. However, the use in the present
study of αGC-loaded CD1d-antitumor fusion proteins,
instead of αGC as a free drug, offers two promising ad-
vantages. Firstly, combining the CD1d-antitumor therapy
with tumor vaccines allows the prolonged reactivity of
iNKT cells to multiple injections of αGC-loaded CD1d
fusion proteins thus sustaining the anti-tumor immune
response [12]. This is in contrast to the iNKT cell anergy
that can already be induced by a single injection of free
αGC, as shown in a large number of pre-clinical studies
[12,17,31-33]. Clinical trials in cancer patients have pre-
ferred the autologous transfer of αGC-pulsed DC, which
showed prolonged iNKT cell activation, as compared to
the glycolipid alone [34-38]. However, clinical responses
remained very limited unless the cancer was directly tar-
geted by infusion of the cells in the proximity of the tumor
[38,39]. In these trials, clinical responses correlated with
the frequency of tumor infiltrating T cells, indicating the
importance of tumor targeted immunotherapy. Thus, the
tumor targeting of αGC is another important advantage of
αGC/sCD1d-antitumor fusion proteins as combinatorial
vaccine agents. We have previously demonstrated that
these tumor targeted fusion proteins are able to induce
direct NKT cell killing of tumor cell lines bearing the spe-
cific target antigen and to redirect both the innate and
adaptive responses to the tumor site, which greatly im-
proves antitumor efficacy [11,12]. Consistent with our
previous work, the present results confirmed the accu-
mulation of both innate and adaptive effector subsets
in the tumor tissue when targeted with the combined
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cells increased in the tumor with or without the OVA/
CpG-ODN vaccine, but most importantly OVA-specific
CTL numbers increased two-fold in the tumors upon
combined OVA/CpG-ODN vaccine and CD1d-anti-HER2
therapy as compared to vaccine alone. The increase in CTL
was greater than the sum of the individual responses of the
vaccine and the CD1d-anti-HER2. This indicates a synergy
between the two treatments, which correlates with the
improved inhibition of tumor growth. Importantly, the
therapeutic efficacy of the combined therapy was com-
pletely abolished upon CD8 T cell depletion but not NK
cell depletion, suggesting a strict requirement of CD8 T
cells. Unexpectedly, these results were in contrast with
previous reports from us and others, demonstrating that
iNKT-cell mediated antitumor activity was dependent on
the transactivation of NK cells [12]. However, when zoom-
ing in on the kinetic of tumor growth with or without NK
cell depletion, their involvement in tumor inhibition was
clearly visible until day 18, when tumor escape usually oc-
curs in these tumor settings [12,31,40]. The addition of
OVA/CpG-ODN immunization induced the activation and
potent expansion of the adoptively transferred OVA-specific
CTLs thus allowing tumor escape to be further delayed.
Conclusions
In conclusion, combined vaccine/CD1d immunotherapy
enhances the activation and recruitment of tumor-specific
CD8 T cells, which appears to be favored by the local
inflammation induced by activated iNKT and NK cell
accumulation at the tumor site. Thus, the optimized
DC maturation and antigen-presentation at the tumor
site upon repeated CD1d-mediated immunotherapy has
the potential to prolong the anti-tumor CTL response, in
addition to providing an additional adjuvant boost to the
initial active antitumor vaccination. It is becoming evident
that the combination of different therapies is the most
promising tool available to improve the clinical outcome
of existing therapeutic cancer vaccines, and here we dem-
onstrate a way to enhance vaccine efficacy by harnessing
two anti-tumor immune pathways to produce a powerful
synergistic anti-tumor effect.
Methods
Animals, cell lines, vaccine and other reagents
Mice were maintained at the University of Lausanne’s
Specific Pathogen Free Unit. C57BL/6 mice were obtained
from Harlan Laboratories (The Netherlands), and CD45.1
congenic B6.SJL-PtprcaPep3b/BoyJArc breeders were
purchased from Charles River, L’Arbresle (France), and
bred on site. TCR-transgenic OT-I mice were originally
obtained from Jackson Laboratories (USA), and bred on
site. Vα14-Jα18 TCR transgenic mice were kindly pro-
vided by A. Bendelac, University of Chicago (USA) [41],and were bred on site. Age and sex-matched mice be-
tween 6–14 weeks of age were used for all experiments.
This study was approved by the Veterinary authority of
the Canton of Vaud (Permit #1605), and experiments were
performed in accordance with Swiss ethical guidelines.
The B16 melanoma cell line was stably transduced
with the retroviral vector pLPcx containing the human
HER2, and subsequently transfected with pcDNA3.1
containing the cytoplasmic part of ovalbumin (residues
45–378 [42]). The double positive B16-OVA/HER2 cell
line was maintained under puromycin and neomycin
selection. The H-2Kb-restricted OVA257–264 epitope was
synthetized at the Protein and Peptide Chemistry Facility
of the University of Lausanne. CpG-ODN 1826 (Class B)
was purchased from InvivoGen Europe (France). The
CD1d super agonist α-galactosylceramide (αGC) KRN7000
was purchased from Enzo Life Science.
Recombinant CD1d-anti-HER2 fusion protein and CD1d
tetramer
The CD1d-anti-HER2 fusion protein was essentially
produced and purified as described previously [12].
Shortly before systemic treatment, proteins were loaded
with a 2.5 fold excess of αGC KRN7000, and unbound gly-
colipid was removed by size exclusion FPLC. Integrity and
absence of aggregates, as well as endotoxin contamination
were regularly checked by respectively SDS-PAGE, FPLC
and LAL bioassay. Recombinant proteins were used if
endotoxin level was <0.5EU/μg protein corresponding to
<0.04 ng endotoxin/μg of protein. The CD1d tetramer
was produced as previously described [11].
Flow cytometry analysis and cytokine bead array analysis
Cells were stained first with the MHC-class-I/SIINFEKL
tetramer at RT for 30 min, then, CD1d tetramer was
added for additional 30 min on ice. Surface staining
antibodies were added without wash and incubated for
20 min on ice. Cells were washed once with PBS 2%FCS
and resuspended in 200 μl of PBS 2%FCS for acquisition.
All fluorochrome-labeled antibodies were purchased from
Becton Dickinson (BD Biosciences) or eBiosciences. Flow
cytometric analyses were performed with a FACSCalibur,
FACSCanto or LSRII cytometer (BD Biosciences) and the
acquired data were processed using FlowJo software (Tree
Star Inc.). Cytokine levels were measured by fluorescence-
based multiplex assay using BD Cytometric Bead Array kit
TH1/TH2/TH17 or BD Mouse IL-12p70 Flex Set Kit
(CBA, BD Biosciences).
Adoptive cell transfer, immunisations and treatments
OVA-specific CD8 T cells and iNKT cells (CD45.2) were
isolated from spleens of OT-I and Vα14-Jα18 mice,
respectively. Single cell suspensions were obtained by
disrupting the lymphoid tissue and the frequency of
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Cells were labeled with Vα2 and β5.1/5.2 antibodies for
OT-I cells and CD1d tetramers and CD3 antibody for
NKT cells. Naive B6-SJ ptp-rca (CD45.1) recipient mice
received an i.v. transfer of 1x105 OT-I cells and 5 × 105
NKT in 200 μl DMEM. One day after the transfer, mice
were vaccinated intra-muscularly (i.m.) with 50 μl of
either PBS, OVA peptide alone (10 μg), OVA peptide
(10 μg) plus CpG-ODN (50 μg) alone, or in combination
with αGC/CD1d-scFv fusion protein (40 μg). Vaccination
was immediately followed by i.v. treatments with 200 μl of
either PBS alone or αGC/CD1d-antitumor scFv fusion
proteins (40 μg). Systemic treatment with the αGC/CD1d-
antitumor scFv fusion proteins (40 μg) was repeated at 2
to 4-day intervals. This schedule was optimized based
on the NKT TCR recycling kinetics following activation/
stimulation as previously published [12].DC maturation
Spleens were harvested 20 hours after the immunisations
and disrupted to obtain a single-cell suspension. Spleno-
cytes were next enriched for CD11c+ cells using the auto-
MACS system (Miltenyi Biotec, Germany). Briefly, cells
were labeled with anti-CD11c microbeads (Miltenyi Biotec),
as per the manufacturer’s protocol, and purified using the
POSSEL program on the AutoMACS. The positive fraction
was recovered for maturation marker analysis by flow
cytometry.Tumor immunotherapy
CD45.1 congenic mice were grafted s.c. in the right flank
with 5 × 105 B16-OVA-HER2 cells. Five days after the
graft, a mix of 5 × 105 Vα14-Jα18 TCR-transgenic.
NKT cells and 1 × 105 OT-I CD8 T cells were transferred
into the mice. Immunisations were performed six days after
the graft as described above. Mean tumor volume, moni-
tored every two days, was calculated using the following
formula (length × width × thickness)/2.Tumor-infiltrating lymphocyte analysis
At day 7 after the vaccination, tumors were harvested and
digested for 40 min at 37°C, according to the Tumor dis-
sociation kit protocol (MACS Miltenyi Biotec, Germany).
Tumors were crushed on 100 μm cell strainers and
washed twice with PBS 2%FCS. Single cell suspensions
were enriched for CD45+ cells using the autoMACS sys-
tem (Miltenyi Biotec, Germany). Briefly, cells from
maximum 500 mg of tumor tissue were labeled with
anti-CD45 microbeads (Miltenyi Biotec), as per the
manufacturer’s protocol, and purified using the POSSEL
program on the AutoMACS. The positive fraction was
recovered for TILs analysis by flow cytometry.Antibody-mediated CD8 and NK cell depletion
CD8 T cells were depleted by repeated i.p. injections of
100 μg of anti-mouse CD8α mAb, clone 53–6.72 (BioXCell,
USA). NK cells were depleted by repeated injections of
50 μl of mouse anti-asialo-GM1 polyclonal Abs suspension
(Wako Pure Chemical). Anti-asialo-GM1 antibodies were
used as an alternative to anti-NK1.1, to avoid the concomi-
tant depletion of a large fraction of iNKT cells, which are
NK1.1+, while ensuring specific depletion of NK cells. The
first injection was done two days before the immunisations
and repeated every three or five days for a total of four
injections.
Statistical analysis
Results are expressed as mean ± SEM. Statistical signifi-
cance was determined with the one-way-ANOVA test
with Bonferroni correction (GraphPad Prism, GraphPad
software). Tumor progression statistics were calculated
with the unpaired t-test for each time-point (GraphPad
Prism, GraphPad software). (*, p <0.05; **, p <0.01; ***,
p <0.001; ****, p <0.0001).
Additional files
Additional file 1: Figure S1. Description of the gating strategy to
discriminate CD8α+ and CD8αneg DCs as well as pDCs is shown. Live
splenocytes from experiment described in Figure 1 were stained for
B220, CD11c, CD11b, MHC II and CD8α. Conventional DCs were gated
as B220negCD11chigh and CD8α+ or CD8αneg. pDCs were identified as
B220+CD11c+.
Additional file 2: Figure S2. The αGC/CD1d-anti-HER2 fusion
cooperates with CpG-ODN to rapidly induce iNKT-mediated activation of NK
cells. A. Mice transferred with Vα14-Jα18 and OT-I cells were immunized i.m.
with OVA peptide alone or in combination with CpG or CD1d-fus/CpG
followed or not by systemic treatment with the CD1d-antitumor protein.
The ex vivo expression of CD69 on NK cells was determined twenty hours
post indicated treatments. Bar graph represents mean of fluorescence of
CD69 on the CD3negNK1.1+ cell population. B. 2 × 105 splenocytes from a
Vα14-Jα18 transgenic mouse were cultured in complete DMEM medium in
presence of either plate-coated αGC/CD1d-anti-HER2 fusion (40 μg/ml),
CpG-ODN (5 μg/ml) or the combination of the two stimuli. Cells were
recovered at 6hours and analyzed by flow cytometry. Bar graph
represents mean of fluorescence of CD69 on CD1d tetramer+ CD3+ iNKT
cell population. ***, p < 0.001; ****, p < 0.0001.
Additional file 3: Figure S3. Cooperative effects of Trp2 peptide/CpG
ODN and CD1d-anti-HER2 fusion protein independently of T and iNKT adoptive
cell transfer. Naive C57BL/6 mice were vaccinated with 20 μg of a short
immunogenic peptide from Tyrosinase-related protein 2 (Trp2 180-188) alone,
with CpG-ODN (50 μg) or with a combination of CpG and CD1d-anti-HER2
fusion (40 μg). Mice were bled 7 days after the immunization. A. Frequency of
H-2Kb/Trp2-specific T cells among circulating CD8+ lymphocytes. B. Frequency
of NK cells among total lymphocytes in the blood. Scatter dot plot graphs
show frequencies as mean +/- SEM of groups of 8 mice. Data are representative
of two independent experiments. *, p < 0.05; ***, p < 0.001.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SC and RP contributed equally to the study design, acquisition of data and
to drafting the manuscript. LZ collaborated to the in vivo experiments and to
the manuscript editing. JP and PR participated to the study design and
Corgnac et al. Journal for ImmunoTherapy of Cancer 2014, 2:39 Page 11 of 12
http://www.immunotherapyofcancer.org/content/2/1/39manuscript editing. AD conceived of the study, and participated in its design
and coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.Acknowledgments
We thank A. Bendelac (University of Chicago, IL, USA), for kindly providing us
with the iNKT transgenic mouse line. The financial support for this study was
provided by the Swiss Cancer League OCS-02248-08-2008 (S. Corgnac),
Vaccinex Inc.; Rochester, NY, USA, and the Emma Muschamp Foundation
(R. Perret).
Author details
1Translational Tumor Immunology Group, Ludwig Center for Cancer
Research, University of Lausanne, Lausanne, Switzerland. 2Department of
Biochemistry, University of Lausanne, Lausanne, Switzerland.
Received: 24 July 2014 Accepted: 8 October 2014
References
1. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E,
Zitvogel L, Kroemer G, Galluzzi L: Trial Watch: peptide vaccines in cancer
therapy. Oncoimmunology 2013, 2:e26621.
2. Palucka K, Banchereau J: Cancer immunotherapy via dendritic cells. Nat
Rev Cancer 2012, 12:265–277.
3. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD: Comparative analysis of
regulatory and effector T cells in progressively growing versus rejecting
tumors of similar origins. Cancer Res 2006, 66:7301–7309.
4. Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, Romero P: Adjuvants
that improve the ratio of antigen-specific effector to regulatory T cells
enhance tumor immunity. Cancer Res 2013, 73:6597–6608.
5. Padte NN, Li X, Tsuji M, Vasan S: Clinical development of a novel
CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol
2011, 140:142–151.
6. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, Mathew B,
Schmidt RR, Lunt SJ, Williams KJ, Stratford IJ, Harris AL, Cerundolo V:
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T
cell-mediated immunotherapy. J Clin Invest 2004, 114:1800–1811.
7. Cerundolo V, Silk JD, Masri SH, Salio M: Harnessing invariant NKT cells in
vaccination strategies. Nat Rev Immunol 2009, 9:28–38.
8. Kulkarni RR, Villanueva AI, Elawadli I, Jayanth P, Read LR, Haeryfar SM, Sharif
S: Costimulatory activation of murine invariant natural killer T cells by
toll-like receptor agonists. Cell Immunol 2012, 277:33–43.
9. Hermans IF, Silk JD, Gileadi U, Masri SH, Shepherd D, Farrand KJ, Salio M,
Cerundolo V: Dendritic cell function can be modulated through
cooperative actions of TLR ligands and invariant NKT cells. J Immunol
2007, 178:2721–2729.
10. Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, Takeshima T, Gyobu H,
Kawarada Y, Kondo S, Akira S, Katoh H, Ikeda H, Nishimura T:
Liposome-encapsulated CpG oligodeoxynucleotides as a potent
adjuvant for inducing type 1 innate immunity. Cancer Res 2004,
64:8754–8760.
11. Corgnac S, Perret R, Derre L, Zhang L, Stirnemann K, Zauderer M, Speiser
DE, Mach JP, Romero P, Donda A: CD1d-antibody fusion proteins target
iNKT cells to the tumor and trigger long-term therapeutic responses.
Cancer Immunol Immunother 2013, 62:747–760.
12. Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M,
Wurm F, Corradin G, Mach JP, Mach JP, Macdonald HR, Donda A: Sustained
activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv
fusion protein induce antitumor effects in mice. J Clin Invest 2008,
118:994–1005.
13. Borst J, Hendriks J, Xiao Y: CD27 and CD70 in T cell and B cell activation.
Curr Opin Immunol 2005, 17:275–281.
14. Keller AM, Xiao Y, Peperzak V, Naik SH, Borst J: Costimulatory ligand CD70
allows induction of CD8+ T-cell immunity by immature dendritic cells in
a vaccination setting. Blood 2009, 113:5167–5175.
15. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita
H, Godfrey DI: Sequential production of interferon-gamma by NK1.1(+) T
cells and natural killer cells is essential for the antimetastatic effect of
alpha-galactosylceramide. Blood 2002, 99:1259–1266.16. Takeda K, Hayakawa Y, Atsuta M, Hong S, Van Kaer L, Kobayashi K, Ito M,
Yagita H, Okumura K: Relative contribution of NK and NKT cells to the
anti-metastatic activities of IL-12. Int Immunol 2000, 12:909–914.
17. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR,
Joyce S, Van Kaer L: Glycolipid antigen induces long-term natural killer T
cell anergy in mice. J Clin Invest 2005, 115:2572–2583.
18. Duthie MS, Windish HP, Fox CB, Reed SG: Use of defined TLR ligands as
adjuvants within human vaccines. Immunol Rev 2011, 239:178–196.
19. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving
beyond current vaccines. Nat Med 2004, 10:909–915.
20. Schlom J: Therapeutic cancer vaccines: current status and moving
forward. J Natl Cancer Inst 2012, 104:599–613.
21. Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan
S, Carreno LJ, Venkataswamy MM, Kim J, Lazar-Molnar E, Lauvau G, Chang
YT, Liu Z, Bittman R, Al-Shamkhani A, Cox LR, Jervis PJ, Veerapen N, Besra
GS, Porcelli SA: A single subset of dendritic cells controls the cytokine
bias of natural killer T cell responses to diverse glycolipid antigens.
Immunity 2014, 40:105–116.
22. Shimizu K, Asakura M, Shinga J, Sato Y, Kitahara S, Hoshino K, Kaisho T,
Schoenberger SP, Ezaki T, Fujii S: Invariant NKT cells induce plasmacytoid
dendritic cell (DC) cross-talk with conventional DCs for efficient memory
CD8+ T cell induction. J Immunol 2013, 190:5609–5619.
23. Van Kaer L: NKT cells: T lymphocytes with innate effector functions. Curr
Opin Immunol 2007, 19:354–364.
24. Hunn MK, Hermans IF: Exploiting invariant NKT cells to promote T-cell
responses to cancer vaccines. Oncoimmunology 2013, 2:e23789.
25. Mattarollo SR, Smyth MJ: NKT cell adjuvants in therapeutic vaccines
against hematological cancers. Oncoimmunology 2013, 2:e22615.
26. Vincent MS, Leslie DS, Gumperz JE, Xiong X, Grant EP, Brenner MB:
CD1-dependent dendritic cell instruction. Nat Immunol 2002, 3:1163–1168.
27. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM: The linkage of innate to
adaptive immunity via maturing dendritic cells in vivo requires CD40
ligation in addition to antigen presentation and CD80/86 costimulation.
J Exp Med 2004, 199:1607–1618.
28. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A:
Cutting edge: cross-talk between cells of the innate immune system:
NKT cells rapidly activate NK cells. J Immunol 1999, 163:4647–4650.
29. Ferlazzo G, Morandi B: Cross-talks between natural killer cells and distinct
subsets of dendritic cells. Front Immunol 2014, 5:159.
30. Caielli S, Conforti-Andreoni C, Di Pietro C, Usuelli V, Badami E, Malosio ML,
Falcone M: On/off TLR signaling decides proinflammatory or tolerogenic
dendritic cell maturation upon CD1d-mediated interaction with invariant
NKT cells. J Immunol 2010, 185:7317–7329.
31. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y:
Sequential activation of NKT cells and NK cells provides effective innate
immunotherapy of cancer. J Exp Med 2005, 201:1973–1985.
32. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM: Activation of natural
killer T cells by alpha-galactosylceramide rapidly induces the full
maturation of dendritic cells in vivo and thereby acts as an adjuvant for
combined CD4 and CD8 T cell immunity to a coadministered protein.
J Exp Med 2003, 198:267–279.
33. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R,
Sato H, Kondo E, Koseki H, Taniguchi M: CD1d-restricted and TCR-mediated
activation of valpha14 NKT cells by glycosylceramides. Science 1997,
278:1626–1629.
34. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson
A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K,
Hassoun H, Steinman RM, Dhodapkar MV: Sustained expansion of NKT cells
and antigen-specific T cells after injection of alpha-galactosyl-ceramide
loaded mature dendritic cells in cancer patients. J Exp Med 2005,
201:1503–1517.
35. Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-gamma-
producing NKT response induced with alpha-galactosylceramide-loaded
DCs. Nat Immunol 2002, 3:867–874.
36. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M,
Iizasa T, Nakayama T, Taniguchi M, Fujisawa T: A phase I study of alpha-
galactosylceramide (KRN7000)-pulsed dendritic cells in patients with
advanced and recurrent non-small cell lung cancer. Clin Cancer Res
2005, 11:1910–1917.
37. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T,
Macfarlane DJ, Nicol AJ: Therapeutic activation of Valpha24 + Vbeta11+
Corgnac et al. Journal for ImmunoTherapy of Cancer 2014, 2:39 Page 12 of 12
http://www.immunotherapyofcancer.org/content/2/1/39NKT cells in human subjects results in highly coordinated secondary
activation of acquired and innate immunity. Blood 2004, 103:383–389.
38. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S,
Taniguchi M, Nakayama T, Okamoto Y: Phase I study of alpha-
galactosylceramide-pulsed antigen presenting cells administration
to the nasal submucosa in unresectable or recurrent head and neck
cancer. Cancer Immunol Immunother 2008, 57:337–345.
39. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S,
Sakurai D, Taniguchi M, Nakayama T, Okamoto Y: Combination therapy of
in vitro-expanded natural killer T cells and alpha-galactosylceramide-
pulsed antigen-presenting cells in patients with recurrent head and neck
carcinoma. Cancer Sci 2009, 100:1092–1098.
40. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I,
Okumura K: Critical contribution of IFN-gamma and NK cells, but not
perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-
galactosylceramide. Eur J Immunol 2001, 31:1720–1727.
41. Griewank K, Borowski C, Rietdijk S, Wang N, Julien A, Wei DG, Mamchak AA,
Terhorst C, Bendelac A: Homotypic interactions mediated by Slamf1 and
Slamf6 receptors control NKT cell lineage development. Immunity 2007,
27:751–762.
42. Schuler P, Contassot E, Irla M, Hugues S, Preynat-Seauve O, Beermann F,
Donda A, French LE, Huard B: Direct presentation of a melanocyte-
associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T
cells. Cancer Res 2008, 68:8410–8418.
doi:10.1186/s40425-014-0039-8
Cite this article as: Corgnac et al.: iNKT/CD1d-antitumor immunotherapy
significantly increases the efficacy of therapeutic CpG/peptide-based
cancer vaccine. Journal for ImmunoTherapy of Cancer 2014 2:39.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
